Literature DB >> 1952061

Synthesis of peptide analogues using the multipin peptide synthesis method.

R M Valerio1, M Benstead, A M Bray, R A Campbell, N J Maeji.   

Abstract

Modification of the multipin peptide synthesis method which allows the simultaneous synthesis of large numbers of different peptide analogues is described. Peptides were assembled on polyethylene pins derivatized with a 4-(beta-alanyloxymethyl)benzoate (beta-Ala-HMB) handle. For comparative purposes, peptides were also assembled on the diketopiperazine-forming handle N epsilon-(beta-alanyl)lysylprolyloxylactate. In model studies it was demonstrated that beta-Ala-HMB-linked peptides were cleaved from polyethylene pins with dilute sodium hydroxide or 4% methylamine/water to yield analogues with beta-Ala-free acid (beta-Ala-CO2H) and beta-Ala-methylamide (beta-Ala-CONHCH3), respectively. To assess the suitability of this approach for T-cell determinant analysis, analogues of a known T-cell determinant were synthesized with the various C-terminal endings. Peptides were characterized by amino acid analysis and fast atom bombardment-mass spectrometry. HPLC of the crude cleaved peptides indicated that 22 of the 24 peptides were greater than 95% pure. These crude peptide solutions were nontoxic in sensitive cell culture assays without further purification. All three cleavage procedures gave comparable activities in T-cell proliferation assays. These results demonstrate the potential of the multipin peptide synthesis method for the production of large numbers of different peptide analogues.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1952061     DOI: 10.1016/0003-2697(91)90374-3

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  8 in total

1.  Mapping of neutralizing epitopes on Renibacterium salmoninarum p57 by use of transposon mutagenesis and synthetic peptides.

Authors:  Gregory D Wiens; Jennifer Owen
Journal:  Appl Environ Microbiol       Date:  2005-06       Impact factor: 4.792

2.  CCL5-independent helper T lymphocyte responses to immuno-dominant pneumococcal surface protein A epitopes.

Authors:  Rajesh Singh; Shailesh Singh; David E Briles; Dennis D Taub; Susan K Hollingshead; James W Lillard
Journal:  Vaccine       Date:  2011-12-14       Impact factor: 3.641

3.  Unusually high frequency of Epstein-Barr virus genetic variants in Papua New Guinea that can escape cytotoxic T-cell recognition: implications for virus evolution.

Authors:  J M Burrows; S R Burrows; L M Poulsen; T B Sculley; D J Moss; R Khanna
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

4.  A new strategy for solid phase synthesis of a secondary amide library using sulfonamide linker via radical traceless cleavage.

Authors:  Juntao Luo; Wenqiang Huang
Journal:  Mol Divers       Date:  2003       Impact factor: 2.943

5.  Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers.

Authors:  Rebecca Elkington; Susan Walker; Tania Crough; Moira Menzies; Judy Tellam; Mandvi Bharadwaj; Rajiv Khanna
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

6.  Changes at peptide residues buried in the major histocompatibility complex (MHC) class I binding cleft influence T cell recognition: a possible role for indirect conformational alterations in the MHC class I or bound peptide in determining T cell recognition.

Authors:  W Chen; J McCluskey; S Rodda; F R Carbone
Journal:  J Exp Med       Date:  1993-03-01       Impact factor: 14.307

7.  Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells.

Authors:  S C Jameson; F R Carbone; M J Bevan
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

8.  T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen.

Authors:  S R Burrows; S L Silins; D J Moss; R Khanna; I S Misko; V P Argaet
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.